Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet  | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347672 (1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347675 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 21 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347667 (1-(4-((2-((3-Methoxy-5-(2-morpholinoethoxy)phenyl)...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 22 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM256621 (US9481648, Ref Cpd A | US9790209, Example 2) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 24 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347667 (1-(4-((2-((3-Methoxy-5-(2-morpholinoethoxy)phenyl)...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 31 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347673 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 37 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 40 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347669 (1-(4-((2-((6-(2-(Dimethylamino)ethoxy)pyridin-2-yl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 46 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM256621 (US9481648, Ref Cpd A | US9790209, Example 2) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347660 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 60 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347672 (1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 61 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 67 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347671 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 74 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347666 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 81 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347660 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 85 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347662 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 87 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347662 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 113 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347675 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 148 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347672 (1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 152 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347671 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 158 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347666 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 185 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347672 (1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 202 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347673 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 203 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347662 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 203 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347671 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 214 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347673 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 222 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347665 (1-(4-((2-((3-(2-(Dimethylamino)ethoxy)phenyl)amino...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 243 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347666 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 271 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347673 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 273 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347671 (3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 275 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 296 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347675 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 348 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| 5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM256621 (US9481648, Ref Cpd A | US9790209, Example 2) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 380 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347663 (3-Methoxy-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 539 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347664 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 602 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347660 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347669 (1-(4-((2-((6-(2-(Dimethylamino)ethoxy)pyridin-2-yl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.76E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347667 (1-(4-((2-((3-Methoxy-5-(2-morpholinoethoxy)phenyl)...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.57E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347668 (1-(2,3-Dichloro-4-((2-((7-methyl-1H-indazol-5-yl)a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347676 (1-(4-((2-((6-(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347670 (1-(4-((2-((4-(2-(Dimethylamino)ethoxy)pyridin-2-yl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347662 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347675 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347666 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM347660 (1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Glycogen synthase kinase-3 alpha (Homo sapiens (Human)) | BDBM256621 (US9481648, Ref Cpd A | US9790209, Example 2) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
